1-3 of 3
Claudia Morales de Partovi
Close
Sort by
Journal Articles

Pilot Study of Pembrolizumab for Immunoprevention in Smoldering Multiple Myeloma

Elisabet E. Manasanch, MD, Rohit Mathur, PhD, Hans C. Lee, MD, Donna M. Weber, MD, Krina K. Patel, MDMSc, Sheeba K. Thomas, MD, Silvia C. Munoz, RN, Claudia Morales de Partovi, Catherine M. Claussen, MS, Pei Lin, MDDM,MDC, Behrang Amini, MD, Linghua Wang, Man Chun John MA, PhD, Yun Qing, Feng Lei, MS, Veera Baladandayuthapani, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3089.
https://doi.org/10.1182/blood.V130.Suppl_1.3089.3089
Published: 2017
Journal Articles

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Robert Z. Orlowski, M.D., Ph.D, Shadia Zaman, Ph.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, MD, Ashley N. Holloway, R.N., Veerabhadran Baladandayuthapani, Ph.D., Heather Yan Lin, Ph.D., Min Fu, Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha Gandhi, PhD
Journal: Blood
Blood (2013) 122 (21): 1953.
https://doi.org/10.1182/blood.V122.21.1953.1953
Published: 2013
Journal Articles

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Stephan Joseph Dorkhom, D.O., Shadia Zaman, Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, M.D., Martha L. Anderson, R.N., Veerabhadran Baladandayuthapani, Ph.D., Yan Heather Lin, Ph.D., Min Fu, Ph.D., Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha V. Gandhi, Ph.D., Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2012) 120 (21): 2976.
https://doi.org/10.1182/blood.V120.21.2976.2976
Published: 2012